Thermo Fisher Scientific IGFBP3 Polyclonal Antibody, PeproTech

Applications and Tested Dilutions

Product Specifications

Product Specific Information

AA Sequence of recombinant protein:
GASSGGLGPV VRCEPCDARA LAQCAPPPAV CAELVREPGC GCCLTCALSE GQPCGIYTER CGSGLRCQPS PDEARPLQAL LDGRGLCVNA SAVSRLRAYL LPAPPAPGNA SESEEDRSAG EVESPSVSST HRVSDPKFHP LHSKIIIIKK GHAKDSQRYK VDYESQSTDT QNFSSESKRE TEYGPCRREM EDTLNHLKFL NVLSPRGVHI PNCDKKGFYK KKQCRPSKGR KRGFCWCVDK YGQPLPGYTT KGKEDVHCYS MQSK.

Preparation:
Produced from sera of rabbits immunized with highly pure Recombinant Human IGF-BP3. Anti-Human IGF-BP3-specific antibody was purified by affinity chromatography employing an immobilized Human IGF-BP3 matrix.

Sandwich ELISA:
To detect Human IGF-BP3 by sandwich ELISA (using 100 µL/well antibody solution), a concentration of 0.5–2.0 µg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human IGF-BP3 (500-P230Bt) as a detection antibody, allows the detection of at least 0.2–0.4 ng/well of Recombinant Human IGF-BP3.

Western Blot:
To detect Human IGF-BP3 by Western Blot analysis, this antibody can be used at a concentration of 0.1–0.2 µg/mL. Used with compatible secondary reagents, the detection limit for Recombinant Human IGF-BP3 is 1.5–3.0 ng/lane, under either reducing or non-reducing conditions.

Target Information

IGFBP3 is a gene belonging to the insulin-like growth factor binding protein (IGFBP) family. The encoded protein contains both an IGFBP domain and a thyroglobulin type-I domain. It forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either IGF-I or IGF-II, circulating in plasma to prolong IGF half-life and regulate receptor interactions. Multiple isoforms exist due to alternative splicing. Diseases associated with IGFBP3 include Insulin-Like Growth Factor I and Acid-Labile Subunit Deficiency.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.